JNJ Stock Overview
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 5/6 |
Narratives
BetaNarratives bring a range of perspectives from our community.
Stjepan Kalinic
Equity Analyst and Writer
Price at publication US$160.48
Updated
Goran Damchevski
Equity Analyst
Price at publication US$160.26
Updated
Johnson & Johnson Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$156.76 |
52 Week High | US$175.97 |
52 Week Low | US$144.95 |
Beta | 0.53 |
1 Month Change | 0.13% |
3 Month Change | 0.19% |
1 Year Change | 1.87% |
3 Year Change | -2.33% |
5 Year Change | 14.75% |
Change since IPO | 24,981.64% |
Recent News & Updates
Recent updates
Johnson & Johnson: A Clean Bill Of Health
Feb 28Is There An Opportunity With Johnson & Johnson's (NYSE:JNJ) 43% Undervaluation?
Feb 12Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds
Feb 10Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'
Jan 25Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition
Jan 15Johnson & Johnson: Rock Solid 3% Yield With Over 10% Return Potential (Rating Upgrade)
Jan 04We Think Johnson & Johnson (NYSE:JNJ) Can Manage Its Debt With Ease
Dec 26Johnson & Johnson: Ottava Surgical Robot Is A Growth Tailwind
Dec 23Shareholder Returns
JNJ | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -2.8% | -0.3% | 0.5% |
1Y | 1.9% | 22.4% | 29.0% |
Return vs Industry: JNJ underperformed the US Pharmaceuticals industry which returned 22.4% over the past year.
Return vs Market: JNJ underperformed the US Market which returned 29% over the past year.
Price Volatility
JNJ volatility | |
---|---|
JNJ Average Weekly Movement | 1.8% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: JNJ has not had significant price volatility in the past 3 months.
Volatility Over Time: JNJ's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1886 | 131,900 | Joaquin Duato | https://www.jnj.com |
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke.
Johnson & Johnson Fundamentals Summary
JNJ fundamental statistics | |
---|---|
Market cap | US$377.76b |
Earnings (TTM) | US$13.33b |
Revenue (TTM) | US$85.16b |
28.3x
P/E Ratio4.4x
P/S RatioIs JNJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
JNJ income statement (TTM) | |
---|---|
Revenue | US$85.16b |
Cost of Revenue | US$26.24b |
Gross Profit | US$58.92b |
Other Expenses | US$45.59b |
Earnings | US$13.33b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 16, 2024
Earnings per share (EPS) | 5.53 |
Gross Margin | 69.18% |
Net Profit Margin | 15.65% |
Debt/Equity Ratio | 42.6% |
How did JNJ perform over the long term?
See historical performance and comparison